Cell Care Therapeutics has raised $4.3 million in seed funding from a syndicate of individual investors, the company announced in a press release.
The funding will be used to develop the company’s manufacturing platform and to advance its preclinical-stage drug candidate for eye diseases such as diabetic retinopathy and neovascular age-related macular degeneration, the release said.
“The closing of this first round of financing is an endorsement of our novel approach of using stem cell secretions to modulate the immune system as an alternative to the more commercially challenging
Uncategorized